A
Alain M. Schoepfer
Researcher at University Hospital of Lausanne
Publications - 321
Citations - 16599
Alain M. Schoepfer is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Eosinophilic esophagitis & Medicine. The author has an hindex of 51, co-authored 265 publications receiving 13251 citations. Previous affiliations of Alain M. Schoepfer include University of Zurich & McMaster University.
Papers
More filters
Journal ArticleDOI
Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis
Michel H. Maillard,Murielle Bortolotti,John-Paul Vader,Christian Mottet,Alain M. Schoepfer,Jean-Jacques Gonvers,Bernard Burnand,Florian Froehlich,Florian Froehlich,Pierre Michetti,Valérie Pittet +10 more
TL;DR: Assessment of appropriateness of biological therapies for UC patients found that first-line anti-TNFα therapy results in a greater likelihood of continuing with the therapy, and in situations where biological treatment is uncertain or inappropriate, physicians should consider other options instead of prescribing anti- TNFα agents.
Journal ArticleDOI
309 - Prolongation of Eosinophilic Esophagitis Treatment with Budesonide Orodispersible Tablets for Incomplete Responder is Effective and Safe: Results from a 6-Weeks Open-Label Treatment Phase of the Pivotal Trial EOS-1
Alfredo J. Lucendo,Stephan Miehlke,Michael Vieth,Christoph Schlag,Ulrike von Arnim,Javier Molina-Infante,Dirk Hartmann,Albert J. Bredenoord,Constanza Ciriza de los Ríos,Stefan Schubert,Stefan Brückner,Ahmed Madisch,Jamal O. Hayat,Jan Tack,Stephen Attwood,Ralph Mueller,Roland Greinwald,Alain M. Schoepfer,Alex Straumann +18 more
Journal Article
[Functional gastrointestinal disorders: update on the Rome IV criteria].
Mariola Marx,Hugo Maye,Karim Abdelrahman,Roxane Hessler,Eleni Moschouri,Nurullah Aslan,Sébastien Godat,Cristina Nichita,Paul Wiesel,Laura Perez,Alain M. Schoepfer +10 more
TL;DR: An overview of the current classification of functional gastrointestinal disorders is provided and the most important changes incorporated into the Rome IV criteria are highlighted.
Journal ArticleDOI
540 fluticasone propionate orally disintegrating tablet (apt-1011) improves histologic, endoscopic and symptomatic responses in eosinophilic esophagitis patients with fibro-stenotic features: results from a phase 2b trial
Evan S. Dellon,Gary W. Falk,Alfredo J. Lucendo,Christoph Schlag,Alain M. Schoepfer,Gina Eagle,James Nezamis,Gail M. Comer,Karol Knoop +8 more
Journal ArticleDOI
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
Stephan R. Vavricka,Milos Spasojevic,Gerhard Rogler,Alain M. Schoepfer,Frank Seibold,Jan Borovicka,Pascal Frei,Jonas Zeitz,Thomas Greuter,Christine N. Manser,Michael Scharl,Benjamin Misselwitz,Alex Straumann,Pierre Michetti,Luc Biedermann,Swiss IBDnet +15 more
TL;DR: CZP is an effective long-term treatment option for Crohn's disease, including CD patients with long disease duration and prior treatment with 1 or 2 anti-TNF agents, as well as between patients with a short vs. long duration of disease.